07:13 AM EDT, 07/31/2026 (MT Newswires) -- Futura Medical (FUM.L) said Friday its Eroxon Intense treatment for erectile dysfunction was authorized for commercial launch across the European Economic Area and in the UK. Cooper Consumer Health, Futura's regional commercial partner for Eroxon, holds the option to distribute the new formulation in the European Economic Area and the UK. The consumer healthcare company expects to obtain the US Food and Drug Administration's clearance for Eroxon Intense during the second half.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.